← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
pirenzepine
A02BX03
Forms & Strengths
- Oral tablets: 25 mg, 50 mg
- Intravenous injection: 10 mg/2 mL
Adult Dosing
- Peptic ulcer disease: 50 mg orally twice daily (morning and evening) or 50 mg three times daily for 4-6 weeks
- Maintenance therapy: 25-50 mg orally at bedtime
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established; use is generally not recommended
Indications
- Treatment of gastric and duodenal ulcers
- Reduction of gastric acid secretion
Mechanism of Action
- Selective M1 muscarinic acetylcholine receptor antagonist
- Inhibits gastric acid secretion and pepsin output by blocking M1 receptors on intramural ganglia and parietal cells
Contraindications
- Known hypersensitivity to pirenzepine or other anticholinergics
- Active acute angle-closure glaucoma
- Gastrointestinal obstruction, ileus, or toxic megacolon
- Myasthenia gravis
Adverse Reactions
- Dry mouth
- Blurred vision and accommodation disturbances
- Constipation
- Urinary retention
- Tachycardia
- Dizziness or drowsiness
Drug Interactions
- Enhancement of anticholinergic effects when co-administered with tricyclic antidepressants, antihistamines, or antiparkinsonian drugs
- Potential alteration of gastrointestinal absorption of other drugs due to slowed gastric motility and delayed gastric emptying
Curated Content: Needs Vetting Before Put to Clinical Use